

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

[Docket No. CDC–2021–0036; NIOSH 278]

#### Board of Scientific Counselors, National Institute for Occupational Safety and Health (BSC, NIOSH)

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice of meeting and request for comment.

**SUMMARY:** In accordance with the Federal Advisory Committee Act, the CDC announces the following virtual meeting of the Board of Scientific Counselors, National Institute for Occupational Safety and Health (BSC, NIOSH). This is a virtual meeting. It is open to the public, limited only by web conference lines (500 web conference lines are available). If you wish to attend, please register at the NIOSH website <http://www.cdc.gov/niosh/bsc/> or call (404–498–2581) no later than May 12, 2021. Time will be available for public comment.

**DATES:** The meeting will be held on May 19, 2021, from 10:00 a.m. to 4:00 p.m., EDT.

**ADDRESSES:** This is a virtual meeting. You may submit comments, identified by Docket No. CDC–2021–0036; NIOSH–278 by mail. CDC does not accept comments by email.

- *Federal eRulemaking Portal:* <https://www.regulations.gov>. Follow the instructions for submitting comments.

- *Mail:* Docket number CDC–2021–0036; NIOSH–278, c/o Sherri Diana, NIOSH Docket Office, National Institute for Occupational Safety and Health, 1090 Tusculum Avenue, MS C–34, Cincinnati, Ohio 45226.

*Instructions:* All submissions received must include the Agency name and Docket Number. Written public comments received by May 12, 2021, will be provided to the BSC prior to the meeting. Docket number CDC–2021–0036; NIOSH–278 will close May 12, 2021.

**FOR FURTHER INFORMATION CONTACT:** Emily J.K. Novicki, M.A., M.P.H., Executive Secretary, BSC, NIOSH, CDC, 1600 Clifton Avenue, MS V24–4, Atlanta, Georgia 30329–4027, Telephone (404) 498–2581, or email at [enovicki@cdc.gov](mailto:enovicki@cdc.gov).

#### SUPPLEMENTARY INFORMATION:

*Purpose:* The Secretary, the Assistant Secretary for Health, and by delegation the Director, Centers for Disease Control

and Prevention, are authorized under Sections 301 and 308 of the Public Health Service Act to conduct directly or by grants or contracts, research, experiments, and demonstrations relating to occupational safety and health and to mine health. The Board of Scientific Counselors provides guidance to the Director, National Institute for Occupational Safety and Health on research and prevention programs. Specifically, the Board provides guidance on the Institute's research activities related to developing and evaluating hypotheses, systematically documenting findings and disseminating results. The Board evaluates the degree to which the activities of the National Institute for Occupational Safety and Health: (1) Conform to appropriate scientific standards, (2) address current, relevant needs, and (3) produce intended results.

*Matters To Be Considered:* The agenda for the meeting addresses work-related fatigue, specifically the evolution of workplace fatigue research; the NIOSH Center for Work and Fatigue Research; Emerging issues in workplace fatigue and fatigue management in Agriculture, Forestry and Fishing; Fatigue Management: Technological advances and Fatigue Risk Management Systems; COVID–19 and workplace fatigue: Lessons learned and mitigation strategies; and Global perspectives on workplace fatigue and fatigue risk management.

An agenda is also posted on the NIOSH website (<http://www.cdc.gov/niosh/bsc/>).

*Meeting Information:* It is open to the public, limited only by web conference lines (500 web conference lines are available). Register at the NIOSH website <http://www.cdc.gov/niosh/bsc/> or call (404–498–2581) no later than May 12, 2021.

#### Public Participation

Comments received are part of the public record and are subject to public disclosure. Do not include any information in your comment or supporting materials that you consider confidential or inappropriate for public disclosure. If you include your name, contact information, or other information that identifies you in the body of your comments, that information will be on public display. CDC will review all submissions and may choose to redact, or withhold, submissions containing private or proprietary information such as Social Security numbers, medical information, inappropriate language, or duplicate/near duplicate examples of a mass-mail campaign. CDC will carefully consider

all comments submitted into the docket. CDC does not accept comment by email.

*Oral Public Comment:* The public is welcome to participate during the public comment period, from 3:00 p.m. to 3:15 p.m., EDT, May 19, 2021. Please note that the public comment period ends at the time indicated above. Each commenter will be provided up to five minutes for comment. A limited number of time slots are available and will be assigned on a first come-first served basis. Members of the public who wish to address the BSC NIOSH are requested to contact the Executive Secretary for scheduling purposes (see **FOR FURTHER INFORMATION** above).

*Written Public Comment:* Written comments will also be accepted from those unable to attend the public session per the instructions provided in the address section above. Written comments received in advance of the meeting will be included in the official record of the meeting. Written comments received by May 12, 2021, will be provided to the BSC prior to the meeting. Docket number CDC–2021–0036; NIOSH–278 will close May 12, 2021.

The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

**Kalwant Smagh,**

*Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.*

[FR Doc. 2021–06927 Filed 4–2–21; 8:45 am]

**BILLING CODE 4163–18–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA–2017–N–6397]

#### Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Food Labeling; Calorie Labeling of Articles of Food in Vending Machines and Nutrition Labeling of Standard Menu Items in Restaurants and Similar Retail Food Establishments

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA or we) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

**DATES:** Submit written comments (including recommendations) on the collection of information by May 5, 2021.

**ADDRESSES:** To ensure that comments on the information collection are received, OMB recommends that written comments be submitted to <https://www.reginfo.gov/public/do/PRAMain>. Find this particular information collection by selecting “Currently under Review—Open for Public Comments” or by using the search function. The OMB control number for this information collection is 0910–0782. Also include the FDA docket number found in brackets in the heading of this document.

**FOR FURTHER INFORMATION CONTACT:** Domini Bean, Office of Operations, Food and Drug Administration, Three White Flint North, 10A–12M, 11601 Landsdown St., North Bethesda, MD 20852, 301–796–5733, [PRAStaff@fda.hhs.gov](mailto:PRAStaff@fda.hhs.gov).

**SUPPLEMENTARY INFORMATION:** In compliance with 44 U.S.C. 3507, FDA

has submitted the following proposed collection of information to OMB for review and clearance.

**Food Labeling; Calorie Labeling of Articles of Food in Vending Machines and Nutrition Labeling of Standard Menu Items in Restaurants and Similar Retail Food Establishments**

*OMB Control Number 0910–0782—Extension*

This information collection supports FDA regulations under part 101 (21 CFR part 101) and the associated collection instrument Form FDA 3757. The Federal Food, Drug, and Cosmetic Act requires the disclosure of certain calorie labeling of articles of food in vending machines, as well as nutrition information for standard menu items in certain restaurants and retail food establishments. Sections 101.8 and 101.11 (21 CFR 101.8 and 101.11) provides that respondents with a chain of 20 or more locations will disclose nutritional information of certain foods for consumers of food products for the purpose of making informed dietary choices. We also offer registration for respondents who wish to voluntarily participate with this information collection activity, for which we developed Form FDA 3757 entitled “DHHS/FDA Menu and Vending Machine Labeling Voluntary

Registration” to assist respondents in this regard. To keep the registration active, a respondent renews their registration every other year within 60 days prior to the expiration of the respondent’s current registration with FDA, or it will automatically expire.

We use the collection of information to help determine compliance with regulatory requirements. Third-party disclosure requirements are used by consumers of food products for the purpose of making informed dietary choices.

*Description of Respondents:* Respondents to this collection of information are vending machine operators and restaurants or other similar food establishments that are subject to the requirements of part 101 as well as those entities that voluntarily participate with the provisions of this collection of information.

In the **Federal Register** of December 4, 2020 (85 FR 78334), we published a 60-day notice requesting public comment on the proposed collection of information. Although some general comments were received regarding the applicable labeling requirements, no comments suggested we revise the information collection burden we estimate under 5 CFR 1320.5(a)(1)(B).

We estimate the burden of this collection of information as follows:

**TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN <sup>1</sup>**

Activity using Form FDA 3757; 21 CFR section	Number of respondents	Number of responses per respondent	Total annual responses	Average burden per response	Total hours
Initial Registration for Vending Machine Labeling; 101.8(d) .....	13	1	13	2 .....	26
Registration Renewal for Vending Machine Labeling; 101.8(d) .....	19	1	19	0.5 (30 minutes) ...	9.5
Initial Registration for Menu Labeling; 101.11(d) .....	3,559	1	3,559	2 .....	7,118
Registration Renewal for Menu Labeling; 101.11(d) .....	5,340	1	5,340	0.5 (30 minutes) ...	2,670
<b>Total</b> .....					<b>9,823.5</b>

<sup>1</sup> There are no capital costs or operating and maintenance costs associated with this collection of information.

**TABLE 2—ESTIMATED RECORDKEEPING BURDEN <sup>1</sup>**

Activity; 21 CFR section	Number of record-keepers	Number of records per recordkeeper	Total annual records	Average burden per recordkeeping	Total hours
Initial Burden (Annualized over 3 years):					
Initial Nutrition Analysis; 101.8(c)(2)(i)(A) .....	69,017	1	69,017	0.25 (15 minutes)	17,254
Annual Burden:					
Recurring Nutrition Analysis; 101.8(c)(2)(i)(A) .....	30,059	1	30,059	0.25 (15 minutes)	7,515
<b>Total</b> .....					<b>24,769</b>

<sup>1</sup> There are no capital costs or operating and maintenance costs associated with this collection of information.

**TABLE 3—ESTIMATED ANNUAL THIRD-PARTY DISCLOSURE BURDEN <sup>1</sup>**

Activity; 21 CFR section	Number of respondents	Number of disclosures per respondent	Total annual disclosures	Average burden per disclosure	Total hours
Calorie Analysis; 101.8(c)(2)(i) .....	282	11	3,102	1 .....	3,102
Calorie Declaration Signage; 101.8(c)(2)(ii) .....	3,279	2,122	6,958,038	0.21 (12.5 minutes).	1,461,188

TABLE 3—ESTIMATED ANNUAL THIRD-PARTY DISCLOSURE BURDEN<sup>1</sup>—Continued

Activity; 21 CFR section	Number of respondents	Number of disclosures per respondent	Total annual disclosures	Average burden per disclosure	Total hours
Vending Operator Contact Information; 101.8(e)(1) .....	3,279	125	409,875	0.025 (1.5 minutes).	10,247
Total .....	.....	.....	.....	.....	1,474,537

<sup>1</sup> There are no capital costs or operating and maintenance costs associated with this collection of information.

Based on a review of the information collection since our last request for OMB approval, we have made no adjustments to our burden estimate.

Dated: March 30, 2021.

**Lauren K. Roth,**

*Acting Principal Associate Commissioner for Policy.*

[FR Doc. 2021–06933 Filed 4–2–21; 8:45 am]

**BILLING CODE 4164–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA–2020–N–1647]

#### Science Advisory Board to the National Center for Toxicological Research Advisory Committee; Notice of Meeting

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) announces a forthcoming virtual public advisory committee meeting of the Science Advisory Board to the National Center for Toxicological Research. The general function of the committee is to provide advice and recommendations to the Agency on research being conducted at the National Center for Toxicological Research (NCTR). At least one portion of the meeting will be closed to the public.

**DATES:** The meeting will be held virtually on May 11, 2021, from 8 a.m. to 5:55 p.m., Central Standard Time, and on May 12, 2021 from 8 a.m. to 11:30 a.m., Central Standard Time.

**ADDRESSES:** Please note that due to the impact of this COVID–19 pandemic, all meeting participants will be joining this advisory committee meeting via an online teleconferencing platform. Answers to commonly asked questions about FDA advisory committee meetings may be accessed at: <https://www.fda.gov/advisory-committees/about-advisory-committees/common-questions-and-answers-about-fda-advisory-committee-meetings>. The meeting will be webcast both days and

will be available at the following link: <https://collaboration.fda.gov/nctr1000/>.

#### FOR FURTHER INFORMATION CONTACT:

Donna Mendrick, National Center for Toxicological Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 2208, Silver Spring, MD 20993–0002, 301–796–8892, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area). A notice in the **Federal Register** about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the Agency's website at <https://www.fda.gov/advisory-committees> and scroll down to the appropriate advisory committee meeting link, or call the advisory committee information line to learn about possible modifications before joining the meeting.

#### SUPPLEMENTARY INFORMATION:

**Agenda:** On May 11, 2021, the Science Advisory Board Chair will welcome the participants, and the NCTR Director will provide a Center-wide update on scientific initiatives and accomplishments during the past year. The Science Advisory Board will be presented with an overview of the Science Advisory Board Subcommittee Site Visit Report and a response to this review. The Center for Biologics Evaluation and Research, Center for Drug Evaluation and Research, Center for Devices and Radiological Health, Center for Food Safety and Applied Nutrition, Center for Tobacco Products, and the Office of Regulatory Affairs will each briefly discuss their specific research strategic needs and potential areas of collaboration.

On May 12, 2021, there will be updates from the NCTR Research Divisions and a public comment session. Following an open discussion of all the information presented, the open session of the meeting will close so the Science Advisory Board members can discuss personnel issues at NCTR.

FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background

material on its website prior to the meeting, the background material will be made publicly available at <https://collaboration.fda.gov/nctr1000/>, and the recording plus transcript will be posted on FDA's website after the meeting. Background material is available at <https://www.fda.gov/advisory-committees/advisory-committee-calendar>. Scroll down to the appropriate advisory committee meeting link.

**Procedure:** On May 11, 2021, from 8 a.m. to 5:55 p.m., Central Standard Time, and May 12, 2021, from 8 a.m. to 11:30 a.m., Central Standard Time, the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person (see **FOR FURTHER INFORMATION CONTACT**) on or before May 4, 2021. Oral presentations from the public will be scheduled between approximately 1 p.m. and 2 p.m. Central Standard Time. Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before April 26, 2021. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by April 27, 2021.

**Closed Committee Deliberations:** On May 12, 2021, from 11:30 a.m. to 12 p.m., Central Standard Time, the meeting will be closed to permit discussion where disclosure would constitute a clearly unwarranted invasion of personal privacy (5 U.S.C. 552b(c)(6)). This portion of the meeting will be closed to permit discussion of information concerning individuals